NeuroPace Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
NPCE$12.69-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| (in thousands) | 2024 | 2023 |
| Cash flows from operating activities | ||
| Net loss | $(21,891) | $(26,756) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 7,679 | 7,201 |
| Depreciation | 159 | 132 |
| Amortization of debt discount and issuance costs | 179 | 207 |
| Non-cash interest expense | 743 | 775 |
| PIK interest incurred but not paid on term loan | 1,389 | 1,994 |
| Amortization of right-of-use asset | 1,159 | 1,064 |
| (Gain) loss on short-term investments | (315) | 580 |
| Inventory write-downs | 196 | 132 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | 753 | (3,798) |
| Inventory | (1,066) | (179) |
| Prepaid expenses and other assets | 621 | 1,530 |
| Accounts payable | (102) | (815) |
| Accrued liabilities | (1,108) | 2,623 |
| Deferred revenue | (341) | — |
| Operating lease liabilities | (1,207) | (1,050) |
| Net cash used in operating activities | (13,152) | (16,360) |
| Cash flows from investing activities | ||
| Acquisition of property and equipment | (267) | (141) |
| Proceeds from sale of short-term investments | 7,300 | 19,700 |
| Net cash provided by investing activities | 7,033 | 19,559 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock under employee plans | 1,336 | 254 |
| Taxes withheld and paid related to net share settlement of equity awards | (789) | (222) |
| Proceeds from at-the-market offering, net of sales commission | 2,932 | — |
| Payment of deferred offering costs | — | (119) |
| Net cash provided by (used in) financing activities | 3,479 | (87) |
| Net (decrease) increase in cash and cash equivalents | (2,640) | 3,112 |
| Cash, cash equivalents and restricted cash | ||
| Beginning of the period | 18,180 | 6,727 |
| End of the period | $15,540 | $9,839 |
| Reconciliation of cash, cash equivalents and restricted cash to balance sheets: | ||
| Cash and cash equivalents | $15,418 | $9,717 |
| Restricted cash | 122 | 122 |
| Cash, cash equivalents and restricted cash in balance sheets | $15,540 | $9,839 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $4,294 | $3,305 |
| Supplemental disclosures of non-cash investing and financing information: | ||
| Deferred offering costs offset against additional paid-in capital | $99 | $— |
| Net change in accrued liabilities from early exercise of options | $(1) | $(1) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.